Research PubMed / Gynecol Endocrinol clinical-researchpelvic-healthchronic-pain

DT56a (Femarelle) effectively manages vulvovaginal atrophy in postmenopausal women.

PubMed / Gynecol Endocrinol · 2026-09-06 · By Nachtigall M, Nachtigall LE · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

A study published in Gynecological Endocrinology examined the effectiveness of DT56a (Femarelle), a non-hormonal phytoestrogen-based compound, in treating vulvovaginal atrophy (VVA) among postmenopausal women. The findings suggest the agent may offer a viable option for managing VVA symptoms in this population. Pelvic floor physical therapists who treat genitourinary syndrome of menopause may find these results relevant when coordinating care with prescribing clinicians.

Read full article at PubMed / Gynecol Endocrinol ↗

About this summary. The text above is a short summary written for this site. The original article is hosted by PubMed / Gynecol Endocrinol at the link above; this site does not reproduce the full article. Verify against the source before relying on specific details.